Achieving clinical response in postpartum depression leads to improvement in health-related quality of life
- PMID: 33719782
- DOI: 10.1080/03007995.2021.1902295
Achieving clinical response in postpartum depression leads to improvement in health-related quality of life
Abstract
Objective: To evaluate the health-related quality of life (HRQoL) burden associated with postpartum depression (PPD), determine the extent to which clinical response impacts HRQoL, and estimate the impact of PPD and clinical response on healthcare resource utilization (HRU) and productivity.
Methods: Patient data (n = 127) from two multicenter, randomized, double-blind, placebo-controlled phase 3 clinical trials evaluating the safety and efficacy of brexanolone injection in adults with PPD were employed for these posthoc analyses. HRQoL and health utility was assessed with the SF-36-v2 Health Survey (SF-36v2) acute version. The 17-item Hamilton Rating Scale for Depression (HAMD-17) total score was used to identify clinical response (≥50% reduction in HAMD-17 total score). Baseline HRQoL burden was assessed by comparison to age- and gender-adjusted population normative data from the 2009 QualityMetric PRO Norming study. The impact of clinical response was evaluated by comparing day 7 and day 30 SF-36v2 scores between clinical responders and non-responders. Interpretations of the meaningfulness of clinical response were indirectly estimated via 2017 National Health and Wellness Survey data linking SF-36v2 mental component summary (MCS) scores to (HRU) and productivity.
Results: Baseline HRQoL of patients with PPD was significantly below normative values. Day 7 and day 30 clinical response were associated with large and statistically significant improvements in HRQoL, greater likelihood of meeting SF-36v2 responder definitions, and reduced impairment. MCS levels corresponding to those observed in clinical responders were linked to lower HRU and productivity loss relative to non-responders.
Conclusions: PPD places a substantial burden on HRQoL. Achievement of rapid clinical response (at day 7) and clinical response sustained several weeks following the end of treatment (day 30) led to significant improvement in HRQoL, suggesting the importance of identifying women with PPD and providing effective treatment options.
Keywords: Postpartum depression; SF-36v2 Health Survey; health-related quality of life; healthcare resource utilization; productivity.
Similar articles
-
Patients' perspective on the burden of migraine in Europe: a cross-sectional analysis of survey data in France, Germany, Italy, Spain, and the United Kingdom.J Headache Pain. 2018 Sep 10;19(1):82. doi: 10.1186/s10194-018-0907-6. J Headache Pain. 2018. PMID: 30203163 Free PMC article.
-
Patient-reported health-related quality of life from a randomized, placebo-controlled phase 2 trial of zuranolone in adults with major depressive disorder.J Affect Disord. 2022 Jul 1;308:19-26. doi: 10.1016/j.jad.2022.03.068. Epub 2022 Apr 2. J Affect Disord. 2022. PMID: 35378149 Clinical Trial.
-
Effect of brexanolone on depressive symptoms, anxiety, and insomnia in women with postpartum depression: Pooled analyses from 3 double-blind, randomized, placebo-controlled clinical trials in the HUMMINGBIRD clinical program.J Affect Disord. 2023 Jan 1;320:353-359. doi: 10.1016/j.jad.2022.09.143. Epub 2022 Sep 30. J Affect Disord. 2023. PMID: 36191643 Clinical Trial.
-
Brexanolone for postpartum depression.Am J Health Syst Pharm. 2020 Feb 19;77(5):336-345. doi: 10.1093/ajhp/zxz333. Am J Health Syst Pharm. 2020. PMID: 32073124 Review.
-
Brexanolone for Postpartum Depression: Clinical Evidence and Practical Considerations.Pharmacotherapy. 2019 Nov;39(11):1105-1112. doi: 10.1002/phar.2331. Epub 2019 Oct 7. Pharmacotherapy. 2019. PMID: 31514247 Review.
Cited by
-
GABAkines - Advances in the discovery, development, and commercialization of positive allosteric modulators of GABAA receptors.Pharmacol Ther. 2022 Jun;234:108035. doi: 10.1016/j.pharmthera.2021.108035. Epub 2021 Nov 16. Pharmacol Ther. 2022. PMID: 34793859 Free PMC article. Review.
-
Brexanolone, zuranolone and related neurosteroid GABAA receptor positive allosteric modulators for postnatal depression.Cochrane Database Syst Rev. 2025 Jun 26;6(6):CD014624. doi: 10.1002/14651858.CD014624.pub2. Cochrane Database Syst Rev. 2025. PMID: 40562419 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical